DNA methylation and lipid metabolism: an EWAS of 226 metabolic measures

Clinical Epigenetics

Table 3 Results of the investigation into associations between CpG sites associated with metabolic measures and clinical outcomes, and the effect on associations when adjusting for lipid-lowering drug intake

CpG	Gene	Outcome	Model 1: Without adjustment for intake of lipid-lowering drugs				Model 2: Adjustment for intake of lipid-lowering drugs				Significant in
CpG	Gene	Outcome	Beta value M1	P_M1	Bonf P M1	OR (95% CI) M1	Beta value M2	P_M2	Bonf P M2	OR (95%_CI) M2	Significant in
cg19693031	TXNIP	Diabetes	− 0.56	4.33E−09	2.08E−07	0.57 (0.47–0.69)	− 0.59	1.32E−09	6.32E−08	0.55 (0.46–0.67)	M1 and M2
cg06500161^a	ABCG1	MI	0.70	2.87E−05	1.38E−03	2.02 (1.45–2.8)	0.41	2.56E−02	1	1.5 (1.05–2.15)	M1 only
cg17901584	DHCR24	MI	− 0.65	4.37E−04	2.10E−02	0.52 (0.37–0.75)	− 0.17	4.04E−01	1	0.85 (0.57–1.25)	M1 only
cg06500161^b	ABCG1	obesity	0.35	3.94E−08	1.89E−06	1.42 (1.25–1.61)	0.36	2.54E−08	1.22E−06	1.43 (1.26–1.63)	M1 and M2
cg27243685^b	ABCG1	Obesity	0.29	5.56E−06	2.67E−04	1.34 (1.18–1.52)	0.30	3.96E−06	1.90E−04	1.35 (1.19–1.53)	M1 and M2
cg00574958^b	CPT1A	Obesity	− 0.29	3.30E−06	1.58E−04	0.75 (0.66–0.85)	− 0.29	2.86E−06	1.37E−04	0.75 (0.66–0.84)	M1 and M2
cg07504977^b	LINC00263	Obesity	0.21	1.02E−03	4.87E−02	1.23 (1.09–1.39)	0.21	1.04E−03	4.98E−02	1.23 (1.09–1.39)	M1 and M2
cg16246545^b	PHGDH	Obesity	− 0.29	5.88E−07	2.82E−05	0.74 (0.66–0.84)	− 0.29	1.27E−06	6.11E−05	0.75 (0.67–0.84)	M1 and M2
cg06690548^b	SLC7A11	Obesity	− 0.31	2.75E−07	1.32E−05	0.73 (0.65–0.83)	− 0.30	3.76E−07	1.80E−05	0.74 (0.66–0.83)	M1 and M2
cg11024682^b	SREBF1	Obesity	0.34	1.26E−06	6.03E−05	1.4 (1.22–1.6)	0.34	1.34E−06	6.45E−05	1.4 (1.22–1.6)	M1 and M2

Associations of CpG site-clinical outcome in the KORA F4 cohort. Clinical outcomes: previous myocardial infarction, prevalent type 2 diabetes, obesity, and prevalent hypertension. Model 1: logistic regression model with clinical outcome as dependent variable and technically adjusted methylation value as independent variable, adjusted for the following covariates: age, sex, BMI (except for obesity model), C-reactive protein levels, hemoglobin A1c levels (except for diabetes model), history of myocardial infarction (except for the myocardial infarction model), smoking status, alcohol intake, current hypertension (except for the hypertension model), physical activity, white blood cell count, and estimated proportions of white blood cell types. Model 2: additionally adjusted for intake of lipid-lowering drugs (yes/no). Only statistically significant results are shown. P: p value; M1: model 1; M2: model 2; OR: odds ratio for a 1 standard deviation increase in methylation; CI: confidence interval
^aAssociation using KORA F4 data in [15]
^bAssociation using KORA F4 data in [25]

ISSN: 1868-7083